UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Lung cancer (Amsterdam, Netherlands), 2019-08, Vol.134, p.174-179

2019

Volltextzugriff (PDF)

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Annals of oncology, 2016-09, Vol.27 (9), p.1712-1718

2016

Volltextzugriff (PDF)

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Annals of oncology, 2023-04, Vol.34 (4), p.377-388

2023

Volltextzugriff (PDF)

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Annals of oncology, 2019-10, Vol.30, p.v917-v918

2019

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407

Annals of oncology, 2018-10, Vol.29, p.viii748-viii749

2018

Volltextzugriff (PDF)

Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup

Annals of oncology, 2018-11, Vol.29, p.ix151-ix151

2018

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Volltextzugriff (PDF)

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S216-S217

2019

Volltextzugriff (PDF)

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Lung cancer (Amsterdam, Netherlands), 2019-09, Vol.135, p.188-195

2019

Volltextzugriff (PDF)

335 RICTOR amplification as a novel molecular target for the treatment of lung cancer

European journal of cancer (1990), 2014-11, Vol.50, p.108-109

2014

Volltextzugriff (PDF)

Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3495-3501

2005

Volltextzugriff (PDF)

A misfired Greenfield filter; 21 years later

QJM, 2009-01, Vol.102 (1), p.69-70

2009

Volltextzugriff (PDF)

1328P Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices

Annals of oncology, 2020-09, Vol.31, p.S856-S856

2020

Volltextzugriff (PDF)

105P Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S755-S755

2021

Volltextzugriff (PDF)

108P Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S756-S757

2021

Volltextzugriff (PDF)

Treating Hepatocellular Carcinoma With Sorafenib in Liver Transplant Patients: An Initial Experience

Transplantation proceedings, 2010-12, Vol.42 (10), p.4582-4584

2010

Volltextzugriff (PDF)

P2.16-17 Real-World Trends in Systemic Therapy for Nonsquamous EGFR/ALK-Negative Advanced NSCLC (aNSCLC) in the US, 2011–2018

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S871-S872

2019

Volltextzugriff (PDF)

P1.16-42 Real-World Trends in Systemic Anticancer Therapy (SACT) for Squamous Advanced NSCLC (aNSCLC) in the US, 2011–2018

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S604-S604

2019

Volltextzugriff (PDF)

P2.16-41 Pembrolizumab for Previously Treated, PD-L1–Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S882-S882

2019

Volltextzugriff (PDF)

P1.16-15 Rates of Systemic Anticancer Therapy (SACT) for Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US, 2011–2018

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S592-S592

2019

Volltextzugriff (PDF)

MO01.20 Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-Line Nonsquamous NSCLC: A Matching-Adjusted Indirect Comparison

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S24-S24

2021

Volltextzugriff (PDF)

MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S23-S23

2021

Volltextzugriff (PDF)

MO01.19 An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab+Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S23-S24

2021

Volltextzugriff (PDF)

P01.05 Pilot Study of Inhaled Azacitidine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S237-S238

2021

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(101)

Publikationsform

Artikel
(101)

Sprache

Englisch
(101)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(10)
Oncology
(9)
Female
(8)
Male
(8)
Middle Aged
(7)
Adult
(6)
Aged
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(6)
Pembrolizumab
(6)
Aged, 80 And Over
(5)
Lung Neoplasms - Drug Therapy
(5)
Respiratory System
(5)
Biological And Medical Sciences
(4)
Chemotherapy
(4)
Medical Sciences
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Biomarker
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1–positive advanced NSCLC: Pooled analysis from KEYNOTE-010, -024, and -042

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407

Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

335 RICTOR amplification as a novel molecular target for the treatment of lung cancer

Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma

A misfired Greenfield filter; 21 years later

1328P Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices

105P Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data

108P Real-world time on treatment (rwToT) analysis for first-line pembrolizumab combination therapy in advanced nonsquamous NSCLC

Treating Hepatocellular Carcinoma With Sorafenib in Liver Transplant Patients: An Initial Experience

P2.16-17 Real-World Trends in Systemic Therapy for Nonsquamous EGFR/ALK-Negative Advanced NSCLC (aNSCLC) in the US, 2011–2018

P1.16-42 Real-World Trends in Systemic Anticancer Therapy (SACT) for Squamous Advanced NSCLC (aNSCLC) in the US, 2011–2018

P2.16-41 Pembrolizumab for Previously Treated, PD-L1–Expressing Advanced NSCLC: Real-World Time on Treatment and Overall Survival

P1.16-15 Rates of Systemic Anticancer Therapy (SACT) for Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US, 2011–2018

MO01.20 Pembrolizumab+Chemo versus Atezolizumab+Chemo+/-Bevacizumab for First-Line Nonsquamous NSCLC: A Matching-Adjusted Indirect Comparison

MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC

MO01.19 An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab+Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1

P01.05 Pilot Study of Inhaled Azacitidine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern